Genomic and Proteomic Network for Premature Birth Reseach

用于早产研究的基因组和蛋白质组网络

• 批准号: 7171599
• 负责人: MICHAEL W. VARNER
• 金额: $ 74.05万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7171599
• 关键词: Accounting; Arts; Caring; Child health care; Class; Clinical; Clinical Research; Clinical Trials; Clinics and Hospitals; Communities; Community Hospitals; Enrollment; Genes; Genetic; Genetic Polymorphism; Genomics; Health Sciences; Healthcare Systems; International; Medical Genetics; Medicine; Molecular; Multicenter Trials; National Institute of Child Health and Human Development; Patients; Population; Premature Birth; Productivity; Proteomics; Publishing; Reporting; Research; Research Design; Research Infrastructure; Sampling Studies; Specialist; Techniques; Universities; Utah; Woman; cDNA Arrays; cytokine; experience; fetal; myometrium; reproductive; stillbirth; tertiary care

DESCRIPTION (provided by applicant): This proposal constitutes the University of Utah application for the NICHD Genomic and Proteomic Network for Premature Birth Research. The University of Utah has numerous unique strengths that make it an ideal center for the network. These include: I. Research Productivity in Multicenter Collaborative Studies: The University of Utah Maternal-Fetal Medicine (MFM) Division has made substantial contributions to over 15 multicenter clinical trials during the past five years and is a leading recruitment center for the NICHD/MFMU Network. Over 12,000 Utah patients were enrolled in the recently completed FASTER trial, accounting for almost 32% of subjects in the 12- center trial. The University of Utah also participates in the Stillbirth Collaborative Research Network and the Global Network for Women's and Children's Health Research. II. Premature Birth: The University of Utah enjoys international recognition as a center of excellence for clinical care and research on premature birth. III. Expertise in the Use of Genomic and Proteomic Techniques to Study Premature Birth: The Maternal-Fetal Medicine Division has published on the use of cDNA microarray to identify genes with labor-specific expression within myometrium and has also reported on cytokine polymorphisms and spontaneous preterm birth in various ethnic populations. We have also recently reported experience with the use of proteomics to identify potential predictors of term and preterm birth. IV. Reproductive and Medical Genetics: Utah's distinct population has attracted numerous world-class geneticists to the University. State of the art molecular and clinical genetic capabilities will be made available to the Network. V. University / Community Synergy: MFM specialists in Utah have a unique clinical and research partnership that crosses competing health care systems and affords universal access to patients for clinical research. VI. Proven Enrollment Strategy: Research infrastructure is currently in place at four regional tertiary care centers that has and will continue to allow the University of Utah to be among the leading recruitment centers for large multicenter trials.

描述（由申请人提供）：本提案构成犹他大学对 NICHD 早产研究基因组和蛋白质组网络的申请。犹他大学拥有众多独特的优势，使其成为理想的网络中心。其中包括： I. 多中心合作研究的研究生产力：犹他大学母胎医学 (MFM) 部门在过去五年中为超过 15 项多中心临床试验做出了重大贡献，是 NICHD/MFMU 的领先招募中心网络。最近完成的 FASTER 试验招募了超过 12,000 名犹他州患者，几乎占 12 中心试验受试者的 32%。犹他大学还参加了死产合作研究网络和全球妇女和儿童健康研究网络。二.早产：犹他大学作为早产临床护理和研究的卓越中心而享有国际认可。三．使用基因组和蛋白质组技术研究早产的专业知识：母胎医学部发表了关于使用 cDNA 微阵列来识别子宫肌层内具有分娩特异性表达的基因的文章，并且还报道了细胞因子多态性和自发性早产。各民族人口。我们最近还报告了使用蛋白质组学来识别足月和早产的潜在预测因素的经验。四．生殖和医学遗传学：犹他州独特的人口吸引了众多世界级的遗传学家来到该大学。最先进的分子和临床遗传能力将提供给网络。 V. 大学/社区协同：犹他州的 MFM 专家拥有独特的临床和研究合作伙伴关系，跨越竞争的医疗保健系统，并为患者提供普遍的临床研究机会。六．行之有效的招生策略：目前四个地区三级护理中心已具备研究基础设施，这些中心已经并将继续使犹他大学成为大型多中心试验的领先招募中心之一。